MCID: LRG001
MIFTS: 48

Large Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Large Cell Carcinoma

MalaCards integrated aliases for Large Cell Carcinoma:

Name: Large Cell Carcinoma 12 15
Carcinoma, Large Cell 44 70
Carcinoma Large Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4552
MeSH 44 D018287
NCIt 50 C3780
SNOMED-CT 67 22687000
UMLS 70 C0206704

Summaries for Large Cell Carcinoma

Disease Ontology : 12 A carcinoma that is composed of large, monotonous rounded or overtly polygonal-shaped cells with abundant cytoplasm.

MalaCards based summary : Large Cell Carcinoma, also known as carcinoma, large cell, is related to lung large cell carcinoma and pleomorphic carcinoma. An important gene associated with Large Cell Carcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Developmental Biology and p70S6K Signaling. The drugs Everolimus and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and thyroid, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Large Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 551)
# Related Disease Score Top Affiliating Genes
1 lung large cell carcinoma 32.5 SYP ROS1 NKX2-1 NCAM1 MTOR FGFR1
2 pleomorphic carcinoma 32.0 NKX2-1 KRT7 EGFR
3 large cell neuroendocrine carcinoma 31.3 SYP NKX2-1 NCAM1 KRT7 ERBB2 ENO2
4 carcinoid syndrome 30.6 SYP ENO2 CHGA
5 lymphoepithelioma-like carcinoma 30.4 KRT7 KRT19 ENO2 EGFR
6 pulmonary large cell neuroendocrine carcinoma 30.4 SYP STK11 NCAM1 CHGA
7 intestinal obstruction 30.3 MTOR KRT7 CEACAM5
8 neuroendocrine carcinoma 30.1 TP63 SYP NKX2-1 NCAM1 KRT7 KRT19
9 small cell carcinoma 30.0 SYP NKX2-1 NCAM1 KRT7 KRT19 ERBB2
10 basaloid squamous cell carcinoma 29.9 TP63 SYP KRT7 KRT19 ENO2 EGFR
11 lung cancer 29.8 TP63 SYP STK11 ROS1 PTHLH NKX2-1
12 bladder urothelial carcinoma 29.8 MTOR HRAS FGFR1 ERBB2
13 solid adenocarcinoma with mucin production 29.7 ROS1 NKX2-1 NCAM1 KRT7 KRT5 CHGA
14 neuroendocrine tumor 29.7 SYP NKX2-1 NCAM1 MTOR KRT19 HRAS
15 neurofibromatosis, type i 29.6 NCAM1 MTOR HRAS ENO2 EGFR
16 benign mesothelioma 29.6 NKX2-1 KRT7 KRT5 KRT19 CEACAM5
17 adenocarcinoma 29.6 STK11 ROS1 NKX2-1 KRT7 HRAS FGFR1
18 tubular adenocarcinoma 29.5 SYP KRT7 ERBB2 ENO2 EGFR CHGA
19 suppression of tumorigenicity 12 29.5 SYP HRAS ERBB2 EGFR CHGA
20 bronchiolo-alveolar adenocarcinoma 29.5 NKX2-1 KRT7 HRAS EGFR CEACAM5
21 signet ring cell adenocarcinoma 29.5 KRT7 HRAS ERBB2 CHGA CEACAM5
22 in situ carcinoma 29.4 KRT5 HRAS ERBB2 EGFR
23 lung disease 29.4 SFTPB NKX2-1 ENO2 EGFR CEACAM5
24 adenosquamous carcinoma 29.3 TP63 SYP NKX2-1 KRT7 KRT5 KRT19
25 small cell cancer of the lung 29.3 SYP NKX2-1 NCAM1 KRT7 ENO2 EGFR
26 thymic carcinoma 29.3 TP63 SYP NKX2-1 KRT7 KRT19 ENO2
27 peripheral nervous system disease 29.2 SYP NCAM1 MTOR HRAS ERBB2 ENO2
28 lung squamous cell carcinoma 29.2 TP63 STK11 ROS1 PTHLH KRT19 HRAS
29 squamous cell carcinoma 29.0 TP63 STK11 PTHLH KRT7 KRT19 HRAS
30 adenoid cystic carcinoma 28.8 TP63 NCAM1 KRT7 KRT5 KRT19 HRAS
31 lung cancer susceptibility 3 28.6 STK11 SFTPB ROS1 NKX2-1 KRT7 KRT19
32 thymus large cell carcinoma 11.4
33 large cell carcinoma with rhabdoid phenotype 11.3
34 lung occult large cell carcinoma 11.3
35 lung mixed small cell and squamous cell carcinoma 11.2
36 large cell keratinizing variant squamous cell breast carcinoma 11.2
37 primary hepatic neuroendocrine carcinoma 10.5 SYP CHGA
38 malignant melanocytic neoplasm of the peripheral nerve sheath 10.5 SYP ENO2
39 ovary neuroendocrine neoplasm 10.5 SYP KRT7
40 gastrointestinal neuroendocrine benign tumor 10.5 SYP CHGA
41 optic nerve astrocytoma 10.5 SYP ENO2
42 cerebral neuroblastoma 10.5 SYP ENO2
43 neuronal intestinal dysplasia, type b 10.5 SYP ENO2
44 mixed ductal-endocrine carcinoma 10.4 SYP CHGA
45 sinonasal undifferentiated carcinoma 10.4 SYP ENO2
46 gastric gastrinoma 10.4 ENO2 CHGA
47 papillary tumor of the pineal region 10.4 SYP ENO2
48 pineal region teratoma 10.4 SYP ENO2
49 lung combined type small cell carcinoma 10.4 SYP NCAM1
50 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.4 SYP ENO2

Graphical network of the top 20 diseases related to Large Cell Carcinoma:



Diseases related to Large Cell Carcinoma

Symptoms & Phenotypes for Large Cell Carcinoma

GenomeRNAi Phenotypes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.48 EGFR HRAS MTOR NCAM1
2 Decreased viability GR00055-A-2 10.48 EGFR HRAS MTOR
3 Decreased viability GR00221-A-1 10.48 EGFR HRAS MTOR DDR2 FGFR1 ROS1
4 Decreased viability GR00221-A-2 10.48 HRAS DDR2 FGFR1 ROS1
5 Decreased viability GR00221-A-3 10.48 HRAS
6 Decreased viability GR00221-A-4 10.48 EGFR MTOR DDR2
7 Decreased viability GR00249-S 10.48 ROS1
8 Decreased viability GR00342-S-1 10.48 MTOR ROS1
9 Decreased viability GR00342-S-2 10.48 MTOR
10 Decreased viability GR00386-A-1 10.48 FGFR1
11 Decreased viability GR00402-S-2 10.48 DDR2
12 Decreased cell migration GR00055-A-2 10.02 NCAM1
13 Decreased cell migration GR00055-A-3 10.02 EGFR HRAS MTOR NCAM1
14 Decreased viability with paclitaxel GR00179-A-1 9.35 EGFR MTOR
15 Decreased viability with paclitaxel GR00179-A-2 9.35 MTOR
16 Decreased viability with paclitaxel GR00179-A-3 9.35 EGFR MTOR
17 Decreased cell viability after pRB stimulation GR00230-A-1 8.96 DDR2
18 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 8.8 FGFR1 MTOR ROS1

MGI Mouse Phenotypes related to Large Cell Carcinoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.41 DDR2 EGFR ENO2 ERBB2 FGFR1 KRT19
2 behavior/neurological MP:0005386 10.4 ENO2 ERBB2 FGFR1 HRAS KRT5 MTOR
3 growth/size/body region MP:0005378 10.37 CHGA DDR2 EGFR ENO2 ERBB2 FGFR1
4 cardiovascular system MP:0005385 10.35 CHGA DDR2 EGFR ERBB2 FGFR1 HRAS
5 mortality/aging MP:0010768 10.35 CHGA DDR2 EGFR ERBB2 FGFR1 HRAS
6 endocrine/exocrine gland MP:0005379 10.31 CHGA DDR2 EGFR ERBB2 FGFR1 HRAS
7 craniofacial MP:0005382 10.3 DDR2 EGFR ENO2 ERBB2 FGFR1 HRAS
8 digestive/alimentary MP:0005381 10.25 EGFR ERBB2 FGFR1 HRAS KRT19 KRT5
9 nervous system MP:0003631 10.25 CHGA DDR2 EGFR ENO2 ERBB2 FGFR1
10 integument MP:0010771 10.21 DDR2 EGFR ERBB2 FGFR1 HRAS KRT19
11 muscle MP:0005369 10.11 CHGA DDR2 EGFR ERBB2 FGFR1 HRAS
12 no phenotypic analysis MP:0003012 10.11 CHGA DDR2 EGFR FGFR1 HRAS KRT19
13 neoplasm MP:0002006 10.09 DDR2 EGFR ERBB2 HRAS KRT19 NKX2-1
14 normal MP:0002873 10.06 EGFR ERBB2 FGFR1 HRAS KRT19 MTOR
15 limbs/digits/tail MP:0005371 10.04 DDR2 EGFR ERBB2 FGFR1 KRT5 PTHLH
16 renal/urinary system MP:0005367 9.91 CHGA EGFR FGFR1 HRAS KRT7 MTOR
17 reproductive system MP:0005389 9.9 CHGA DDR2 EGFR ERBB2 FGFR1 KRT19
18 respiratory system MP:0005388 9.7 EGFR ENO2 ERBB2 HRAS KRT19 MTOR
19 skeleton MP:0005390 9.32 DDR2 EGFR ERBB2 FGFR1 HRAS KRT19

Drugs & Therapeutics for Large Cell Carcinoma

Drugs for Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
2
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
3
Carboplatin Approved Phase 4 41575-94-4 10339178 498142 38904
4 Tubulin Modulators Phase 4
5 Antimitotic Agents Phase 4
6 Albumin-Bound Paclitaxel Phase 4
7
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
8 Protein Kinase Inhibitors Phase 3
9 Mitogens Phase 3
10 insulin Phase 3
11 Immunoglobulins Phase 3
12 Insulin, Globin Zinc Phase 3
13 Antibodies, Monoclonal Phase 3
14 Antibodies Phase 3
15
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
16
nivolumab Approved Phase 2 946414-94-4
17
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
18
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
19
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
20
Etoposide Approved Phase 2 33419-42-0 36462
21
Lenograstim Approved, Investigational Phase 2 135968-09-1
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3
23
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
24
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
25 Pharmaceutical Solutions Phase 2
26 Vaccines Phase 1, Phase 2
27 Immunologic Factors Phase 2
28 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
29 Antineoplastic Agents, Immunological Phase 2
30 Angiogenesis Inhibitors Phase 2
31 Etoposide phosphate Phase 2
32 Adjuvants, Immunologic Phase 2
33 Immunoglobulin G Phase 2
34 Immunoglobulins, Intravenous Phase 2
35 Endothelial Growth Factors Phase 2
36 Keratolytic Agents Phase 2
37 Dermatologic Agents Phase 2
38 Podophyllotoxin Phase 2 518-28-5
39 Alkylating Agents Phase 2
40
Pemetrexed Approved, Investigational Phase 1 150399-23-8, 137281-23-3 446556 60843
41
Levoleucovorin Approved, Investigational Phase 1 68538-85-2 149436
42
Crizotinib Approved Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
43
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
44
Glutamic acid Approved, Nutraceutical Phase 1 56-86-0 33032
45
Tyrosine Approved, Investigational, Nutraceutical Phase 1 60-18-4 6057
46 Folic Acid Antagonists Phase 1
47 Vitamin B9 Phase 1
48 Vitamin B Complex Phase 1
49 Folate Phase 1
50
Pembrolizumab Approved 1374853-91-4

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
3 Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology Terminated NCT00673049 Phase 3 CP 751,871 (Figitumumab);Erlotinib;Erlotinib
4 Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
5 A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment Unknown status NCT01497041 Phase 2 Docetaxel;Oxaliplatin
6 A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer Completed NCT00073398 Phase 1, Phase 2
7 Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Recruiting NCT03110978 Phase 2
8 A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) Active, not recruiting NCT01386385 Phase 1, Phase 2 Carboplatin;Paclitaxel;Veliparib
9 A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
10 A Randomized Phase 2 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients Terminated NCT00632203 Phase 2 Temozolomide
11 An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Recruiting NCT04432207 Phase 1 IMU-201 (administered as PD1-Vaxx)
12 A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT02535325 Phase 1 Cisplatin;Methoxyamine;Methoxyamine Hydrochloride;Pemetrexed;Pemetrexed Disodium
13 A Phase 1, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/ALK Inhibitor (PF-02341066) and Pan-Her Inhibitor (PF-0299804) in Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01441128 Phase 1 PF-02341066/PF-00299804;PF-02341066/PF-00299804
14 Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix Recruiting NCT01606293
15 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Recruiting NCT02194738 Carboplatin;Cisplatin;Crizotinib;Erlotinib;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed;Pemetrexed Disodium

Search NIH Clinical Center for Large Cell Carcinoma

Cochrane evidence based reviews: carcinoma, large cell

Genetic Tests for Large Cell Carcinoma

Anatomical Context for Large Cell Carcinoma

MalaCards organs/tissues related to Large Cell Carcinoma:

40
Lung, Breast, Thyroid, Thymus, Ovary, Lymph Node, Appendix

Publications for Large Cell Carcinoma

Articles related to Large Cell Carcinoma:

(show top 50) (show all 1789)
# Title Authors PMID Year
1
Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. 61 54
19339104 2009
2
[Poorly differentiated large cell endocrine carcinoma of the extrahepatic bile ducts]. 54 61
19233580 2009
3
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. 54 61
18452692 2008
4
Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin. 54 61
18078328 2008
5
[Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci]. 61 54
18227018 2008
6
Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. 54 61
18404793 2008
7
Humoral hypercalcemia of malignancy in a patient with large cell carcinoma of the lung: report of case and review of literature. 54 61
17669716 2007
8
Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. 54 61
17192868 2007
9
[Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray]. 54 61
17062341 2006
10
[EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer]. 61 54
17069674 2006
11
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. 61 54
16552419 2006
12
Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. 61 54
15770690 2005
13
CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. 54 61
15722794 2005
14
Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. 54 61
15494931 2004
15
Metastatic bronchogenic carcinoma with human chorionic gonadotropin production manifesting as cerebellar hemorrhage--case report. 61 54
11561353 2001
16
The significance of NSE and CEA as a differentiation marker for the cellular heterogeneity of small cell lung cancer. 61 54
10622207 1999
17
Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression. 61 54
9458138 1997
18
Expression and localization of thrombomodulin in preneoplastic bronchial lesions and in lung cancer. 61 54
9099977 1997
19
Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP). 54 61
9816303 1996
20
GRP receptors are present in non small cell lung cancer cells. 61 54
8806107 1996
21
The expression of trophoblastic cell markers by lung carcinomas. 54 61
7590693 1995
22
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. 61 54
7669560 1995
23
Detection of thrombomodulin in human lung cancer cells. 54 61
8380956 1993
24
Pulmonary large cell carcinoma expressing neuroendocrine markers: the morphological, biological, and neuroendocrine features of their cell lines and surgical cases. 61 54
1331003 1992
25
Carcinoembryonic antigen content in fine needle aspirates of the lung. A diagnostic adjunct to cytology. 61 54
1580109 1992
26
Immunohistochemical detection of cluster 1 small cell lung cancer antigen and chromogranin A in lung carcinomas. 61 54
1315401 1992
27
Activated protooncogenes in human lung tumors from smokers. 61 54
1996309 1991
28
Comparison of cytologic markers for automated lung cancer screening. 54 61
1702634 1990
29
Large cell carcinoma of the lung secreting human chorionic gonadotropin which responded to combination chemotherapy: case report. 54 61
2174998 1990
30
Large cell carcinoma of the lung. Prognostic implications of histopathologic and immunohistochemical subtyping. 61 54
2154087 1990
31
Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer. 61
33485052 2021
32
Lung cancer risk in painters: results from the SYNERGY pooled case-control study consortium. 61
33115922 2021
33
Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report. 61
33605014 2021
34
Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma. 61
33782226 2021
35
MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescence. 61
33684534 2021
36
Cashew apple (Anacardium occidentale L.) extract from a by-product of juice processing: assessment of its toxicity, antiproliferative and antimicrobial activities. 61
33568870 2021
37
Clock dial integrated positioning combined with single utility port video-assisted thoracoscopic surgery: a new localization method for lung tumors. 61
33717587 2021
38
LncRNA CBR3-AS1 potentiates Wnt/β-catenin signaling to regulate lung adenocarcinoma cells proliferation, migration and invasion. 61
33422081 2021
39
Lethal multiple colon necrosis and perforation due to fulminant amoebic colitis: a surgical case report and literature review. 61
33469722 2021
40
[Clinical and Imaging Features of Acute Cerebral Infarction 
in Non-small Cell Lung Cancer Patients with Trousseau Syndrome]. 61
33478185 2021
41
Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer. 61
33628824 2021
42
Primary large cell neuroendocrine carcinoma of the ovary: A rare entity. 61
33716217 2021
43
Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer 61
32512671 2020
44
Lung Cancer Survival in Patients With Autoimmune Disease. 61
33315114 2020
45
Neuroendocrine tumors of the lung: clinicopathological and molecular features. 61
32193632 2020
46
Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study. 61
33010640 2020
47
Atypical and incomplete pulmonary hypertrophic osteoarthropathy in the left distal femur: a case report. 61
33228609 2020
48
Metastatic large cell carcinoma of the lung: A rare cause of acute small bowel obstruction. 61
32915519 2020
49
Primary tumor standardized uptake value (SUVmax) measured on 18F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer. 61
32494919 2020
50
How should molecular findings be integrated in the classification for lung cancer? 61
33209647 2020

Variations for Large Cell Carcinoma

Expression for Large Cell Carcinoma

Search GEO for disease gene expression data for Large Cell Carcinoma.

Pathways for Large Cell Carcinoma

Pathways related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 NCAM1 KRT7 KRT5 KRT19 HRAS FGFR1
2
Show member pathways
12.97 STK11 MTOR HRAS FGFR1 EGFR DDR2
3
Show member pathways
12.89 ROS1 FGFR1 ERBB2 EGFR DDR2
4
Show member pathways
12.89 STK11 MTOR HRAS FGFR1 ERBB2 EGFR
5 12.78 MTOR HRAS FGFR1 ERBB2 EGFR
6
Show member pathways
12.74 MTOR HRAS FGFR1 ERBB2 EGFR
7
Show member pathways
12.69 MTOR HRAS FGFR1 ERBB2 EGFR
8
Show member pathways
12.64 MTOR HRAS FGFR1 ERBB2 EGFR
9
Show member pathways
12.58 MTOR HRAS FGFR1 ERBB2 EGFR
10 12.4 TP63 MTOR HRAS ERBB2 EGFR
11
Show member pathways
12.29 MTOR HRAS FGFR1 EGFR
12
Show member pathways
12.28 MTOR HRAS FGFR1 ERBB2 EGFR
13
Show member pathways
12.27 STK11 MTOR HRAS FGFR1 ERBB2 EGFR
14
Show member pathways
12.24 MTOR HRAS ERBB2 EGFR
15
Show member pathways
12.11 MTOR HRAS FGFR1 ERBB2 EGFR
16 12.11 MTOR HRAS FGFR1 ERBB2 EGFR
17
Show member pathways
12.1 ROS1 MTOR HRAS FGFR1 ERBB2 EGFR
18 12.08 MTOR HRAS ERBB2 EGFR
19 11.94 ROS1 FGFR1 ERBB2 EGFR DDR2
20 11.82 MTOR ERBB2 ENO2 EGFR
21 11.72 SYP NCAM1 FGFR1
22 11.68 HRAS ERBB2 EGFR
23 11.66 FGFR1 ERBB2 EGFR
24 11.61 PTHLH FGFR1 DDR2
25 11.52 HRAS ERBB2 EGFR
26 11.39 FGFR1 ERBB2 EGFR
27 11.36 HRAS FGFR1 EGFR
28 11.29 ROS1 MTOR HRAS
29 11.16 HRAS ERBB2 EGFR
30 10.93 NCAM1 FGFR1 EGFR
31 10.87 MTOR HRAS FGFR1 ERBB2 EGFR
32 10.73 MTOR HRAS ERBB2 EGFR
33 10.23 MTOR HRAS EGFR

GO Terms for Large Cell Carcinoma

Cellular components related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.43 SYP ROS1 HRAS ERBB2 EGFR CHGA
2 receptor complex GO:0043235 9.02 ROS1 FGFR1 ERBB2 EGFR DDR2

Biological processes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 PTHLH HRAS FGFR1 ERBB2 EGFR DDR2
2 phosphorylation GO:0016310 9.95 STK11 ROS1 MTOR FGFR1 ERBB2 EGFR
3 protein phosphorylation GO:0006468 9.91 STK11 ROS1 MTOR FGFR1 ERBB2 EGFR
4 MAPK cascade GO:0000165 9.88 NCAM1 HRAS FGFR1 ERBB2 EGFR
5 positive regulation of protein phosphorylation GO:0001934 9.86 MTOR HRAS ERBB2 EGFR
6 positive regulation of protein kinase B signaling GO:0051897 9.84 MTOR FGFR1 ERBB2 EGFR
7 animal organ morphogenesis GO:0009887 9.81 TP63 SFTPB NKX2-1 HRAS
8 regulation of cell growth GO:0001558 9.74 STK11 ROS1 MTOR
9 positive regulation of epithelial cell proliferation GO:0050679 9.72 HRAS ERBB2 EGFR
10 peptidyl-tyrosine phosphorylation GO:0018108 9.65 ROS1 FGFR1 ERBB2 EGFR DDR2
11 regulation of ERK1 and ERK2 cascade GO:0070372 9.63 ROS1 ERBB2 EGFR
12 positive regulation of MAP kinase activity GO:0043406 9.62 HRAS FGFR1 ERBB2 EGFR
13 cell aging GO:0007569 9.61 TP63 MTOR HRAS
14 anoikis GO:0043276 9.58 STK11 MTOR
15 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.55 ROS1 FGFR1 ERBB2 EGFR DDR2
16 negative regulation of ERBB signaling pathway GO:1901185 9.52 ERBB2 EGFR
17 protein autophosphorylation GO:0046777 9.43 STK11 MTOR FGFR1 ERBB2 EGFR DDR2
18 positive regulation of kinase activity GO:0033674 9.02 ROS1 FGFR1 ERBB2 EGFR DDR2

Molecular functions related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.97 STK11 ROS1 MTOR HRAS FGFR1 ERBB2
2 identical protein binding GO:0042802 9.92 TP63 SYP NCAM1 MTOR FGFR1 ERBB2
3 kinase activity GO:0016301 9.8 STK11 ROS1 MTOR FGFR1 ERBB2 EGFR
4 protein kinase activity GO:0004672 9.7 STK11 ROS1 MTOR FGFR1 ERBB2 EGFR
5 protein tyrosine kinase activity GO:0004713 9.35 ROS1 FGFR1 ERBB2 EGFR DDR2
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 ROS1 FGFR1 ERBB2 EGFR DDR2

Sources for Large Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....